Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21217178 | 0.79 | GABRG2 (0.40) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL19806740 | 0.78 | DDB1 (0.42) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL29773883 | 0.75 | CHRM2 (0.49) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL16637537 | 0.74 | GABRG2 (0.37) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL19805011 | 0.74 | GABRG2 (0.37) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL22960801 | 0.70 | MAPT (0.39) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL16637427 | 0.70 | MAPT (0.41) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL16597821 | 0.70 | GABRG2 (0.42) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL27905863 | 0.69 | CHRM2 (0.49) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL31017644 | 0.69 | CHRM2 (0.46) | GABRG2GABRB3GABRA5GABRA1GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306089-B2 | Gamma-carboline compounds for the detection of Tau aggregates | LIFE MOLECULAR IMAGING LIMITED (GB) | 2022-04-19 | — | — | US | disclosed |
| US-20210047321-A1 | GAMMA-CARBOLINE COMPOUNDS FOR THE DETECTION OF TAU AGGREGATES | Lantheus Biosciences Ltd. (GB) | 2021-02-18 | — | — | US | disclosed |
| US-20210047321-A1 | GAMMA-CARBOLINE COMPOUNDS FOR THE DETECTION OF TAU AGGREGATES | Lantheus Biosciences Ltd. (GB) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306089-B2 | Gamma-carboline compounds for the detection of Tau aggregates | MAPT, PSEN1, PSEN2 | GABRG2 1241/4885GABRB3 688/4885GABRA5 944/4885 |
| US-20210047321-A1 | GAMMA-CARBOLINE COMPOUNDS FOR THE DETECTION OF TAU AGGREGATES | MAPT, PSEN1, PSEN2 | GABRG2 1241/4885GABRB3 688/4885GABRA5 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.